Author: Peter Mansell

Simcyp, a spin-off from the UK’s University of Sheffield that specialises in virtual population-based pharmacokinetic modelling and simulation, is being acquired by translational life sciences company Certara for US$32 million.

Having extended its local remit by taking its commercial operations to the Russian Federation last August, Quintiles is stepping up its clinical development activities in that market through a partnership with investment firm Russian Venture Company (RVC) Biofund.

Selventa, a US-based company specialising in patient stratification for personalised medicine, has signed a multi-year research agreement with Janssen Research & Development focusing on immunological diseases.

Aurelia Bioscience, a preclinical contract research organisation that was among several new companies in the BioCity Nottingham incubator spawned by AstraZeneca’s decision to close its UK R&D site in Charnwood, Leicestershire, is now open for business.

US-based contract research, development and manufacturing organisation Frontage Laboratories has reinforced its already substantial presence in the Chinese market through a US$10 million partnership with Luohe Fanghui Pharmaceuticals, an emerging drug company based in Henan Province.